1. Home
  2. EQS vs SNTI Comparison

EQS vs SNTI Comparison

Compare EQS & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Equus Total Return Inc.

EQS

Equus Total Return Inc.

N/A

Current Price

$0.54

Market Cap

12.3M

Sector

Finance

ML Signal

N/A

Logo Senti Biosciences Inc.

SNTI

Senti Biosciences Inc.

N/A

Current Price

$0.14

Market Cap

10.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
EQS
SNTI
Founded
1991
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.3M
10.4M
IPO Year
1995
2021

Fundamental Metrics

Financial Performance
Metric
EQS
SNTI
Price
$0.54
$0.14
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
★ $13.50
AVG Volume (30 Days)
8.9K
★ 1.2M
Earning Date
01-01-0001
11-24-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 77.31
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$127.27
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.53
$0.14
52 Week High
$2.05
$57.60

Technical Indicators

Market Signals
Indicator
EQS
SNTI
Relative Strength Index (RSI) 33.83 14.66
Support Level N/A N/A
Resistance Level $1.05 $0.24
Average True Range (ATR) 0.05 0.03
MACD -0.01 0.23
Stochastic Oscillator 3.92 4.89

Price Performance

Historical Comparison
EQS
SNTI

About EQS Equus Total Return Inc.

Equus Total Return Inc is a United States-based closed-end management investment company. The company invests mainly in companies pursuing growth either through acquisition or organically, leveraged buyouts, management buyouts, and recapitalizations of existing businesses or special situations, and achieves capital appreciation by making investments in equity and equity-oriented securities issued by privately-owned companies or smaller public companies in transactions.

About SNTI Senti Biosciences Inc.

Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML).

Share on Social Networks: